Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

NCT01487863 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic
Hormone Refractory Prostate Cancer
Castration-resistant Prostate Cancer

Interventions

BIOLOGICAL: sipuleucel-T
DRUG: abiraterone acetate

Sponsor

Dendreon